ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction. On September 3 an ...

The Cooper Companies, Inc.'s (COO) business segment, CooperSurgical (CSI), announced the launch of a new inserter designed for single-hand placement of Paragard on Tuesday, which was recently approved by the FDA. The new single-hand inserter will likely simplify the placement process for healthcare providers, thus making Paragard a more accessible contraceptive choice for both providers and patients. Paragard, a hormone-free intrauterine device (IUD), prevents pregnancy for up to 10 years using copper as th ...

MONTEVIDEO, Uruguay, Sept. 06, 2024 (GLOBE NEWSWIRE) -- dLocal, a leading cross-border payment platform specializing in high-growth markets, announces the appointment of Carlos Menendez as Chief Operating Officer (COO), effective immediately. Jacobo Singer, who currently serves as COO and CoPresident, will continue to serve in both roles during a transition period until December 15, 2024, at which time he will step down from both roles. During this transition period, Carlos and Jacobo will work closely to e ...

Have you assessed how the international operations of The Cooper Companies (COO) performed in the quarter ended July 2024? For this surgical and contact lens products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth jo ...

Core Insights - Cooper Companies experienced a significant share price increase of nearly 12% following the release of its quarterly results, outperforming the S&P 500 index [1] Financial Performance - For the fiscal third quarter, Cooper's revenue exceeded $1 billion, marking an 8% increase compared to the same period in fiscal 2023 [2] - The traditional contact lens supply business contributed approximately $676 million in sales, reflecting a 7% rise, while the CooperSurgical unit generated $327 million, a 9% year-over-year increase [2] - Non-GAAP net income was just below $192 million, or $0.96 per share, representing a 15% increase from the previous year [3] Market Position and Future Outlook - The company is well-positioned to benefit from the aging population in the U.S., as the demographic trend towards an older citizenry is expected to continue [4] - For the fiscal year 2024, management anticipates total revenue to be slightly over $3.89 billion to a bit over $3.91 billion, indicating at least 8% growth from 2023 [5] - Non-GAAP earnings are projected to be between $3.64 and $3.67 per share [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ FORM 10-Q _____________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | --- | --- | |----------------------------------------------------------------- ...

The Cooper Companies, Inc. (COO) delivered adjusted earnings per share (EPS) of 96 cents in the third quarter of fiscal 2024, which improved 14.3% year over year. The figure surpassed the Zacks Consensus Estimate by 5.5%. GAAP EPS for the quarter was 52 cents, indicating a 20.9% increase from the year-ago figure. COO's Revenues in Detail Cooper Companies registered revenues of $1 billion in the fiscal third quarter, up 7.8% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimat ...

Financial Data and Key Metrics Changes - Consolidated quarterly revenues were slightly over $1 billion, up 8% year-over-year [6][17] - Non-GAAP earnings per share grew 14% to $0.96 [6][18] - Consolidated gross margin improved to 66.6%, up from 66.1% last year [18] - Operating margin increased to 25.5% from 23.9% year-over-year [18] - Free cash flow was $118 million with CapEx of $89 million [19] Business Line Data and Key Metrics Changes - CooperVision reported record quarterly revenues of $676 million, up 10% [6][17] - CooperSurgical posted record quarterly revenues of $327 million, up 5%, with fertility sales growing 10% [14][19] - Myopia management portfolio grew 29%, with MiSight up 50% [7][11] Market Data and Key Metrics Changes - The Americas market grew 13%, EMEA 7%, and Asia PAC 7% [7] - The contact lens market grew roughly 7% in calendar Q2, with Cooper taking share up 10% [13] - Fertility clinics are increasing patient activity and upgrading to new technologies [14] Company Strategy and Development Direction - The company aims to become a leader in the daily contact lens space and the global fertility industry [4][5] - Strategic investments include state-of-the-art manufacturing capabilities and technological advancements [5] - The focus remains on delivering advanced fertility solutions and expanding the Myopia management market [14][11] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the healthy state of the market, despite some noise regarding rebates [24] - The company is optimistic about continued growth in both the contact lens and fertility markets [34] - Future guidance includes consolidated revenues of $3.89 billion to $3.91 billion for fiscal 2024, up 8% to 8.5% organically [21] Other Important Information - Two tuck-in acquisitions were completed: ZyMot and obp Surgical, both expected to be accretive to revenue growth and margins [20] - The company is focused on improving free cash flow and reducing net debt, which decreased to $2.5 billion [19] Q&A Session Summary Question: Market conditions and rebate activity - Management indicated that the market remains healthy, with some minor fluctuations in rebate activity [24] Question: Impact of culture media recall on fertility growth - Management confirmed that the fertility team effectively managed the situation, leading to a return to double-digit growth [26] Question: Capacity initiatives in the Americas - Management noted that increased capacity is coming online, which is expected to meet demand and support future growth [28] Question: Pricing dynamics in the contact lens market - Management expects pricing to remain stable, with a 2% to 3% increase supporting market growth [55] Question: Competitive landscape for PARAGARD - Management stated that PARAGARD remains strong in the market, with recent product improvements enhancing its position [59] Question: Myopia management adoption and insurance coverage - Management highlighted ongoing progress in insurance reimbursement and the need for broader adoption of myopia control treatments [72]

The Cooper Companies (COO) reported $1 billion in revenue for the quarter ended July 2024, representing a year-over-year increase of 7.8%. EPS of $0.96 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of +0.57% over the Zacks Consensus Estimate of $997.16 million. With the consensus EPS estimate being $0.91, the EPS surprise was +5.49%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

The Cooper Companies (COO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.49%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.83 per share when it actually produced earnings of $0.85, delivering a surprise of 2.41%. Over ...